Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.49 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.46 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.45 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16860714 | 1.00 | NOD1 (0.49) | NOD1P2RY10GPR174FAAHASAH1 | |
| SCHEMBL29215257 | 0.95 | NOD1 (0.55) | NOD1P2RY10GPR174FAAHASAH1 | |
| SCHEMBL16860735 | 0.95 | NOD1 (0.55) | NOD1P2RY10GPR174FAAHASAH1 | |
| SCHEMBL29215544 | 0.93 | NOD1 (0.57) | NOD1P2RY10GPR174FAAHASAH1 | |
| SCHEMBL16860733 | 0.93 | NOD1 (0.57) | NOD1P2RY10GPR174FAAHASAH1 | |
| SCHEMBL25284318 | 0.93 | NOD1 (0.57) | NOD1P2RY10GPR174FAAHASAH1 | |
| SCHEMBL29215585 | 0.93 | NOD1 (0.57) | NOD1P2RY10GPR174FAAHASAH1 | |
| SCHEMBL8240378 | 0.93 | NOD1 (0.57) | NOD1P2RY10GPR174FAAHASAH1 | |
| SCHEMBL25052917 | 0.93 | NOD1 (0.57) | NOD1P2RY10GPR174FAAHASAH1 | |
| SCHEMBL29875541 | 0.93 | NOD1 (0.57) | NOD1P2RY10GPR174FAAHASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | NOD1 290/4885P2RY10 1128/4885GPR174 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.